New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:32 EDTPOZN, GSK, PTXPernix Therapeutics to acquire TREXIMET tablets for migrain from GlaxoSmithKline
Pernix Therapeutics Holdings (PTX) announced that it has signed an agreement with GlaxoSmithKline (GSK) to acquire the U.S rights to Treximet for the acute treatment of migraine attacks with or without aura in adults. Pernix’s team of approximately 90 specialty sales professionals will support the sales and marketing of Treximet. The transaction: Adds immediate revenues and earnings, FY13 Treximet net sales $78.7M; Leverages Pernix’s existing sales presence and experience across psychiatry and neurology customers; Expected to nearly double Pernix revenues and provide EBITDA margins in excess of 30% on a FY14 pro forma basis; Pernix estimates pro forma FY15 total company revenues will exceed $230M with an EBITDA margin of over 40%. Pernix will make an upfront payment to GSK of $250M for the U.S rights to Treximet. GSK will assign to Pernix the Product Development and Commercialization Agreement between GSK and POZEN (POZN). POZEN and Pernix will amend the PDC Agreement to facilitate further development of Treximet. Pernix expects to begin sales of Treximet immediately following the closing of the transaction with its approximately 90 sales professionals to specific targets in the Neurology, Psychiatry and the Primary Care audiences. Pernix also plans to seek an extension of the exclusivity of Treximet with the first ever pediatric indication for any sumatriptan treatment, expected to file by the end of 2014, as well as additional life-cycle opportunities that are currently being explored. Pernix will pay GSK additional consideration of $17M upon receipt of updated FDA Written Request for pediatric exclusivity.
News For PTX;GSK;POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 17, 2014
09:22 EDTPOZNOn The Fly: Pre-market Movers
HIGHER: Auspex Pharmaceuticals (ASPX), up 83.1% after Phase 3 trial of SD-809 met primary efficacy endpoint... Volcano (VOLC), up 55.3% after Philips (PHG) announced it will acquire the company for $18.00 per share... Paramount Gold and Silver (PZG), up 35.9% after announcing a merger agreement with Coeur Mining... Cerus (CERS), up 17.8% after FDA approves Intercept Blood System... American Apparel (APP), up 15.5% after terminating Dov Charney for cause... TASER (TASR), up 6.1% after LAPD purchases 860 AXON body-worn video cameras... Idera Pharmaceuticals (IDRA), up 5.9% after being called a top 2015 small cap pick at Piper Jaffray... Kandi Technologies (KNDI), up 7.5% after selling 1,000 electric vehicles to Chengdu City... Stillwater Mining (SWC), up 2.7% after being upgraded to Buy from Neutral at Goldman. DOWN AFTER EARNINGS: FedEx (FDX), down 3.5%... Joy Global (JOY), down 1.7%. ALSO LOWER: POZEN (POZN), down 13.1% after receiving a second complete response letter from the FDA for Yosprala... Cliffs Natural (CLF), down 13.1% after price target cut to $1 from $10 at Credit Suisse... Coeur Mining (CDE), down 2.8% following merger agreement with Paramount Gold and Silver.
08:18 EDTPOZNPOZEN to hold a webcast
Management discusses receiving a second complete response letter from the FDA regarding new drug Yosprala in a webcast to be held on December 17 at 8:30 am. Webcast Link
06:34 EDTPOZNPOZEN's NDA for Yosprala candidate receives FDA letter on pending questions
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use